Last reviewed · How we verify
anti-TL1A monoclonal antibody, high dose — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
anti-TL1A monoclonal antibody, high dose (anti-TL1A monoclonal antibody, high dose) — Biocad.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-TL1A monoclonal antibody, high dose TARGET | anti-TL1A monoclonal antibody, high dose | Biocad | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-TL1A monoclonal antibody, high dose CI watch — RSS
- anti-TL1A monoclonal antibody, high dose CI watch — Atom
- anti-TL1A monoclonal antibody, high dose CI watch — JSON
- anti-TL1A monoclonal antibody, high dose alone — RSS
Cite this brief
Drug Landscape (2026). anti-TL1A monoclonal antibody, high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-tl1a-monoclonal-antibody-high-dose. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab